- Home
- BGLC vs APTO Comparison
BGLC vs APTO Comparison
Compare BGLC & APTO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGLC
- APTO
- Stock Information
- Founded
- BGLC 2017
- APTO 1986
- Country
- BGLC Malaysia
- APTO Canada
- Employees
- BGLC N/A
- APTO N/A
- Industry
- BGLC Medical Specialities
- APTO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BGLC Health Care
- APTO Health Care
- Exchange
- BGLC Nasdaq
- APTO Nasdaq
- Market Cap
- BGLC 5.8M
- APTO 6.8M
- IPO Year
- BGLC N/A
- APTO N/A
- Fundamental
- Price
- BGLC $0.25
- APTO $1.71
- Analyst Decision
- BGLC
- APTO Strong Buy
- Analyst Count
- BGLC 0
- APTO 3
- Target Price
- BGLC N/A
- APTO $112.00
- AVG Volume (30 Days)
- BGLC 1.5M
- APTO 58.8K
- Earning Date
- BGLC 05-14-2025
- APTO 05-13-2025
- Dividend Yield
- BGLC N/A
- APTO N/A
- EPS Growth
- BGLC N/A
- APTO N/A
- EPS
- BGLC N/A
- APTO N/A
- Revenue
- BGLC $9,259,858.00
- APTO N/A
- Revenue This Year
- BGLC N/A
- APTO N/A
- Revenue Next Year
- BGLC N/A
- APTO N/A
- P/E Ratio
- BGLC N/A
- APTO N/A
- Revenue Growth
- BGLC N/A
- APTO N/A
- 52 Week Low
- BGLC $0.21
- APTO $1.35
- 52 Week High
- BGLC $1.00
- APTO $50.10
- Technical
- Relative Strength Index (RSI)
- BGLC 35.57
- APTO 26.12
- Support Level
- BGLC $0.23
- APTO $3.20
- Resistance Level
- BGLC $0.29
- APTO $3.43
- Average True Range (ATR)
- BGLC 0.02
- APTO 0.35
- MACD
- BGLC -0.01
- APTO -0.06
- Stochastic Oscillator
- BGLC 20.22
- APTO 13.69
About BGLC BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, effective, and non-invasive liquid biopsy tests for the early detection of biomarkers that it believes are linked to diseases to minimize treatment costs and improve patient management. Its non-invasive blood tests provide analysis of changes in RNA to detect the potential risk of 11 different diseases.
About APTO Aptose Biosciences Inc.
Aptose Biosciences Inc is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities.